ESR1 and breast cancer: It is studied in combination with exemestane or fulvestrant in postmenopausal women with ER+/HER2− advanced BC [188] and is currently under study in combination with another mTOR inhibitor, serabelisib (TAK-117), and paclitaxel for gynecological cancers, including BC [189].